The Inflation Reduction Act (IRA) contains provisions allowing Medicare to negotiate net prices for prescription drugs, but it remains to be seen whether this will translate into savings for beneficiaries, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
The Inflation Reduction Act (IRA) contains provisions allowing Medicare to negotiate net prices for prescription drugs, but it remains to be seen whether this will translate into savings for beneficiaries, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Transcript
The IRA includes provisions to lower prescription drug costs in Medicare. How will they impact beneficiaries?
One of the most noteworthy elements of the health care aspects in the Inflation Reduction Act was for the first time giving Medicare the ability to negotiate for prescription drugs. As you know, value-based insurance design focuses more on out-of-pocket costs than total or net cost of drugs. We like to say Americans don't care about health care costs, they care about what it costs them. So the out-of-pocket elements are more important to us at the V-BID Center. But understanding that there is great consternation and a lot of uncertainty regarding how the Medicare negotiations might happen.
It's being phased in over a number of years focusing on some of the most expensive and popular drugs in the beginning. I've read an awful lot about how this actually might work for consumers but also may backfire, in the fact that there are certain ways around this provision and the fact that launch prices may be increased substantially in the first few years to allow those people who do revenue forecasting to make sure that those innovators who make those drugs are able to achieve what they were hoping to make from a financial perspective. But anything that reduces the cost of drugs to patients at the prescription drug counter is very important to us at the V-BID Center. I'm just hopeful that whatever happens regarding the negotiation of the net price of these drugs translates directly into lower out-of-pocket costs for Medicare beneficiaries.
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More